Protomer engineers next-generation protein therapies that can sense molecular activators in the body. Its chemical biology-based platform enables the development of therapeutic peptides and proteins, including glucose-responsive insulins, with tunable activity that can be controlled with small molecules.

The potential value of the transaction could total more than $1 billion with future development and commercial milestones.

Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's...

Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...

Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term...

Lilly, Merus to develop T-cell redirecting bispecific antibodies
Eli Lilly research and development group Loxo Oncology and oncology firm Merus have signed a research collaboration and exclusive license agreement with...

Lilly to acquire Prevail Therapeutics for $1B
Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion,...